Skip to main content
This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

Deutsche Bank Remains a Buy on Sanofi (SNYNF)

Tipranks - Tipranks - Fri Mar 27, 9:36AM CDT

In a report released today, Emmanuel Papadakis from Deutsche Bank maintained a Buy rating on Sanofi, with a price target of €100.00.

Claim 30% Off TipRanks Premium

Papadakis covers the Healthcare sector, focusing on stocks such as AstraZeneca, GlaxoSmithKline, and Roche Holding AG. According to TipRanks, Papadakis has an average return of 3.5% and a 51.16% success rate on recommended stocks.

In addition to Deutsche Bank , Sanofi also received a Buy from Jefferies’s Michael Leuchten in a report issued today. However, on the same day, TipRanks – xAI reiterated a Hold rating on Sanofi (Other OTC: SNYNF).

See today’s best-performing stocks on TipRanks >>

Based on Sanofi’s latest earnings release for the quarter ending December 31, the company reported a quarterly revenue of €23.74 billion and a net profit of €2 billion. In comparison, last year the company earned a revenue of €11.42 billion and had a net profit of €683 million

Read More on SNYNF:

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).